Summary, slides, & video from the CARB-X + GARDP Bootcamps, 5-8 Sep 2017 ASM-ESCMID Conference

This note was updated on 12 Jan 2018 to provide links to the videos from the bootcamp sessions.

Dear All: 

GARDP + CARB-X have this week hosted Antibiotic Bootcamps #1, #2, and #3 at the ASM-ESCMID conference on antibiotic R&D. There were nearly 350 people registered for the full meeting with good attendance at each Bootcamp. 

Bootcamp #1 (Lynn Silver, Tom Dougherty, Sherman Waddell, and John Tomayko) covered the question of finding interesting start points for R&D: What makes a good hit? What makes a good lead? Who were Lipinski and Oprea and why should you care? Watch the video.

Bootcamp #2 (Tim Keutzer, Evan Hecker, and Mike Young, and Andrew Barlow) took us through the challenges of CMC (Chemistry, Manufacturing, and Controls). Building on the hypothetical case of drug X-1 used for last year’s FDA workshop on developing narrow-spectrum antibiotics, the speakers showed clearly how CMC considerations must be front and center from a very early stage in any development program. Watch the video.

Bootcamp #3 (Erika Matuschek, Kevin Krause, Robin Patel, and Judith Steenbergen) took us through the mysteries of susceptibility testing. It was a soup-to-nuts review that should be reviewed along with the materials from the 13 Sep 2017 FDA-CDRH workshop on diagnostic devices for detecting antimicrobial susceptibility & resistance. Watch the video.

The speakers have also agreed to share their slides.This .zip file (4.4MB) contains the talks from Bootcamps #1 and #2 (note that Bootcamp #2 is provided as a single presentation). And, here is the .zip file (2.3 MB) for the slides from Bootcamp #3. See links after my signature to the individual files.

Again, many thanks to the speakers and to ASM-ESCMID for enabling GARDP & CARB-X to host these events!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Note: If you have trouble unzipping the .zip files, here are links to the individual files provided by the speakers:

Upcoming meetings of interest to the AMR community:

  • 18 Jan 2018 (Geneva): Release of the First Annual Progress Report in support of the UN Sustainable Development Goals (SDG 3 in particular) by the AMR Industry Alliance
  • 12-14 Feb 2018 (Baltimore): ASM Biothreats Conference
  • 28 Feb 2018 (Brussels): Deadline for responses to IMI2 Call 13 (Topic 3) on AMR diagnostics
  • 11-16 Mar 2018 (Ventura Beach): Gordon Research Conference on Antibacterial Discovery
  • 21-24 Apr 2018 (Madrid): ECCMID
  • [NEW] 4-7 Jun 2018 (Boston): BIO (multiple AMR-focused sessions are expected)
  • 7-11 Jun 2018 (Atlanta): ASM Microbe
  • 22-27 Jul 2018 (Bryant University, Smithfield, RI): Gordon Research Conference on Drug Resistance for Cancer, Infectious Disease and Agriculture
  • [Don’t miss this one] 4-7 Sep 2018 ESCMID-ASM Conference (#3) on Drug Development for AMR (Lisbon, Portugal) (initial flyer)
  • 6-14 Oct 2018 International Course on Antibiotics and Resistance (ICARe, Les Pensières, Annecy, France) (link to 2017 program — details pending for 2018)

Share

How the sausage is made: A day of advocacy for PASTEUR

Dear All, Along with more than 50 others, I spent Tuesday 12 Sep 2023 on Capitol Hill visiting offices of members of Congress (Senate and House) seeking support for the PASTEUR Act. If you’re a regular reader, you’ll know that we now have substantial bipartisan support for PASTEUR: it was re-introduced as The Pioneering Antimicrobial

Canada says, “Let’s pull together!” in a major new report

Dear All (and with thanks to Kevin for co-authoring): Yesterday saw the release of a major new report on Pull incentives from Canada! The report’s cover art eloquently summarizes its key message: Well said … and proves that a picture really is worth 1,000 words! Here are the links you’ll need: The report’s webpage at the

€100m HERA Invest fund; Sign to support PASTEUR; Superb AMR movie!

Dear All,  Expanding the available Push funding, the EU’s HERA (Health Emergency Preparedness and Response Authority) has created HERA Invest by allocating €100m in support early and late phases of clinical trials. HERA Invest is open on a rolling application basis to EU-based SMEs developing medical countermeasures that address one of the following cross-border health threats: (i)

Scroll to Top